Ignite Creation Date:
2024-05-06 @ 3:48 PM
Last Modification Date:
2024-10-26 @ 1:57 PM
Study NCT ID:
NCT04763213
Status:
COMPLETED
Last Update Posted:
2021-02-21
First Post:
2021-01-29
Brief Title:
New Predictors in Determining the Need for Invasive Treatment in Non-STEMI
Sponsor:
Kahramanmaras Sutcu Imam University
Organization:
Kahramanmaras Sutcu Imam University
Study Overview
Official Title:
New Predictors in Determining the Need for Invasive Treatment in Non-STEMI During the COVID-19 Pandemic A Retrospective Study
Status:
COMPLETED
Status Verified Date:
2021-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
non-STEMI
Brief Summary:
Non-ST elevation acute coronary syndrome NSTE-ACS is a heterogeneous disease with a wide range of treatment options from the medical follow-up to early invasive treatment due to complete occlusion of the culprit artery Non-ST elevation myocardial infarction acute coronary syndrome NSTEMI-ACS is one of the subcomponents of NSTE-ACS which has an increased mortality rate and for which early intervention can be vital Yet most of these patients require invasive treatment In fact some of them are patients who require very early invasive treatment and have a complete occlusion in the culprit artery Unfortunately risk scoring systems are not sufficient enough to differentiate these patients Therefore the discovery of markers that can be used in the differentiation of NSTEMI-ACS patients with an increased need for invasive treatment andor complete occlusion of the culprits vessels especially during pandemic periods such as the COVID-19 pandemic has gained importance
Inflammation is known to play an important role in the etiopathogenesis of coronary artery disease To the best of our knowledge there is a lack of literature on the relationship between the need for invasive treatment strategy andor complete occlusion of the culprits vessel and the hematological markers in patients diagnosed with NSTEMI-ACS
Inflammation is known to play an important role in the etiopathogenesis of coronary artery disease To the best of our knowledge there is a lack of literature on the relationship between the need for invasive treatment strategy andor complete occlusion of the culprits vessel and the hematological markers in patients diagnosed with NSTEMI-ACS
Detailed Description:
Non-ST elevation acute coronary syndrome NSTE-ACS is a heterogeneous disease with a wide range of treatment options from the medical follow-up to early invasive treatment due to complete occlusion of the culprit artery Non-ST elevation myocardial infarction acute coronary syndrome NSTEMI-ACS is one of the subcomponents of NSTE-ACS which has an increased mortality rate and for which early intervention can be vital In the European Society of Cardiology ESC guidelines NSTEMI-ACS is defined as a high-risk condition that requires diagnostic angiography within 2 hours at the latest in those with very high-risk criteria and within 24 hours at the latest in those who do not have high risk However the non-invasive approach has come to the fore for the NSTEMI-ACS disease due to the COVID-19 pandemic conditions In the recently published national consensus report during the COVID-19 pandemic period medium-high risk NSTEMI-ACS patients are recommended optimal medical therapy as an alternative treatment method even if the diagnosis of COVID-19 was excluded especially in areas where pandemic effects are being experienced intensely Yet most of these patients require invasive treatment In fact some of them are patients who require very early invasive treatment and have a complete occlusion in the culprit artery Unfortunately risk scoring systems are not sufficient enough to differentiate these patients Therefore the discovery of markers that can be used in the differentiation of NSTEMI-ACS patients with an increased need for invasive treatment andor complete occlusion of the culprits vessels especially during pandemic periods such as the COVID-19 pandemic has gained importance
Inflammation is known to play an important role in the etiopathogenesis of coronary artery disease In recent years it has been shown that hematological parameters closely associated with inflammation in people with coronary artery disease may be useful in distinguishing those with increased severity of atherosclerotic involvement and those with high mortality risk The main markers used in studies are Leukocyte count neutrophil-lymphocyte ratio NLR platelet-lymphocyte Ratio PLR systemic immune inflammation index SII red blood cell distribution width RDW and mean platelet volume MPV To the best of our knowledge there is a lack of literature on the relationship between the need for invasive treatment strategy andor complete occlusion of the culprits vessel and the hematological markers in patients diagnosed with NSTEMI-ACS
Inflammation is known to play an important role in the etiopathogenesis of coronary artery disease In recent years it has been shown that hematological parameters closely associated with inflammation in people with coronary artery disease may be useful in distinguishing those with increased severity of atherosclerotic involvement and those with high mortality risk The main markers used in studies are Leukocyte count neutrophil-lymphocyte ratio NLR platelet-lymphocyte Ratio PLR systemic immune inflammation index SII red blood cell distribution width RDW and mean platelet volume MPV To the best of our knowledge there is a lack of literature on the relationship between the need for invasive treatment strategy andor complete occlusion of the culprits vessel and the hematological markers in patients diagnosed with NSTEMI-ACS
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None